Mainz Biomed Continues To Transform Early Cancer Detection Across The Globe

While Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) are making great progress in cancer treatments, the importance of early detection in combating this disease cannot be overstated. Today, a molecular genetics diagnostic company specializing in the early detection of cancer, Mainz Biomed NV (NASDAQ: MYNZ) revealed it made an important step on its mission to provide access to one such diagnostic test to people across the globe and by doing so, providing them with a lifechanging head start in their health battle.

Mainz Biomed Brings Elevated Cancer Diagnostic Capability To Romania

Mainz Biomed just announced it will be launching its flagship product, ColoAlert® in Romania. By entering into a strategic partnership with Bioclinica, a national leader in the Romanian healthcare sector, Mainz Biomed has brought a highly effective and user-friendly at-home detection colorectal cancer test to the Romanian population who has one of the highest CRC incidence rates in Europe without having any national screening program in place. With 1.6 million individuals aged 40 to 49 years, 6.1 million in the 50 to 74 years age box and 1.5 million aged over 75 years, the potential market for ColoAlert® is substantial, reaching 9.2 million tests per year. everaging the renowned expertise and extensive network of Bioclinica, ColoAlert® will immediately become available to a large portion of the Romanian population.

While Europeans make up only one tenth of the world population, they make one fourth of annual cancer cases across the globe. CRC is the second most lethal cancer in Europe and Mainz Biomed’s ColoAlert® is an important step in addressing this challenge.

Innovating Both The Diagnosis And Treatment Landscape Is Essential In Combating Cancer

Back in March, Pfizer bought Seagen, a biological drug developer, for $43 billion to deepen its reach into innovative cancer treatments. Last year, oncology department at Pfizer brought in $12 billion to the revenue table and it had treatments for prostate cancer and breast cancer. With Seagan, Pfizer expanded into treatments for lymph nodes cancer, urinary tract cancer, and colorectal cancer. One year ago, Pfizer deepened its partnership with Erasca in an effort to combine two drugs that complement each other to combat Pancreatic and Colorectal Cancer. mRNA COVID-19 vaccines already saved lives and won a Nobel, as they continue to transform medicine, cancer seems to be the next conquest on their development list.

DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.